REnal Sympathetic dEnervaTion as an a Adjunct to Catheter-based VT Ablation
Completed · Not applicable · Has a placebo group
Conditions studied: Ventricular Tachycardia
In brief
Despite significant advances in the management of ventricular arrhythmias through the use of ICD therapy, AADs, and catheter-based ablation strategies, considerable challenges remain. The optimal method for the prevention of recurrent VT following catheter ablation remains unclear. RSDN may be an effective tool for preventing ventricular arrhythmias, and associated ICD therapies, by reducing central sympathetic tone, catecholamine levels, and the renin-angiotensin- aldosterone system and promoting ventricular remodeling. Although RSDN has been shown to reduce the recurrence of VT in a case report of 2 patients suffering from electrical storm, to date no large prospective randomized study has evaluated the impact of RSDN in the prevention of recurrent VT in patients following catheter ablation of VT with ischemic or non-ischemic ventricular dysfunction. This study will specifically evaluate the safety and efficacy of adjunctive RSDN in the prevention of ICD therapy in patients with ischemic or non-ischemic ventricular dysfunction who are to receive a catheter-based VT ablation.
Key facts
- Study ID
- NCT01858194
- Run by
- Vivek Reddy
- People needed
- 21
- Starts
- 2013-03-01
- Expected to finish
- 2017-09-01
- Last updated by the study team
- 2020-04-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- ≥ 18 years of age
- Structural heart disease (post-MI, dilated cardiomyopathy, sarcoid myopathy, hypertrophic cardiomyopathy, chagas-related cardiomyopathy, etc.)
- Planned for catheter-based ablation of VT
- All patients will have an existing ICD
- Accessibility of renal vasculature (determined by renal angiography)
- Ability to understand the requirements of the study
- Willingness to adhere to study restrictions and comply with all post- procedural follow-up requirements
You may not qualify if…
- MI or CVA within 30 days
- Coronary Artery Bypass Graft (CABG) within 30 days of this procedure
- Known renovascular abnormalities that would preclude RSDN (eg, renal artery stenosis)
- GFR <30 ml/min (unless receiving dialysis)
- Life expectancy <1 year for any medical condition
- Any condition resulting in a contraindication to anticoagulation (e.g. GI bleeding)
- Inability to give informed consent
- Known pregnancy or positive -HCG within 7 days of procedure.
Where it is running
- Icahn School of Medicine at Mount Sinai — New York, New York, United States
- Homolka Hospital — Prague, Czechia
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.